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Acute myeloid leukemia (AML) is a heterogeneous 
disease, which typically affects older people and is 
associated with poor clinical outcomes [1]. Whilst there 
have been significant improvements in AML therapy in 
the last few years, survival rates remain low, coupled 
with high incidence of relapse and therapy resistance 
[2]. The development of all trans retinoic acid (ATRA) 
in the treatment of APL (reviewed in [3]) and tyrosine 
kinase inhibitors (TKI) as targeted therapy in chronic 
myelocytic leukemia (CML) (reviewed in [4]), provide a 
paradigm for targeted therapy in AML. Indeed, revelations 
of novel insights into pathways that lead to the survival 
and proliferation of AML cells is opening new therapeutic 
possibilities [5, 6]. One such possible pathway includes 
reprogramming metabolism. A recent report by our group, 
Robinson et al., 2020, showed that reactive oxygen species 
(ROS) which are inappropriately produced by NAPDH 
oxidase (NOX2) on the surface of AML cells, can alter 
AML cell metabolism to support proliferation [7]. 
Our previous studies linked increased NOX2 
derived ROS production with cellular proliferation in 
human hematopoietic stem and progenitor cells (HSPC) 
[8]. Follow up ex vivo studies showed similar effects in 
AML patient blasts and in vitro AML cell lines models 
[9]. Further, other groups have shown that FLT3-ITD 
AML showed increased levels of ROS which associated 
with increased DNA double strand breaks [10]. Clinically, 
a causal link between ROS level and relapse has been 
established in AML [11], whilst elevated ROS levels have 
also been observed in ALL and CML patient samples [12]. 
Building on work by Hole et al., 2010 [8], our group found 
that HSPC expressing constitutively active RAS not only 
generated increased levels of NOX2 derived ROS, but that 
this ROS specifically led to changes in mRNA expression 
levels of glycolytic enzymes [7]. Data presented in this 
study established for the first time a link between ROS 
production, increased glycolysis and elevated expression 
of the key glycolytic regulatory enzyme, 6-Phosphofructo-
2-Kinase/Fructose-2,6-Biphosphatase 3 (PFKFB3) in 
AML patients. Support for these findings was provided 
using AML cell lines, where ROS levels were depleted 
through chemical inhibition of NOX or knock-down of 
NOX2 using shRNA (THP-1) or increased (using lines 
that generate little NOX2 derived ROS; Mv4;11) through 
the addition of exogenous ROS [7]. Overexpression of 
PFKFB3 in Mv4;11 AML cells was sufficient to in increase 
glucose uptake and cellular proliferation, whilst in cells 
with activated NOX2, chemical inhibition of PFKFB3 
decreased glucose uptake and cellular proliferation in 
THP-1 cells and HSPC expressing mutant RAS. Together, 
these data established a causal link between ROS levels, 
cellular glucose uptake and PFKFB3 activity. 
Mass spectrometry was employed to determine in 
the impact of inhibition of ROS production on metabolism 
in AML cell lines [13]. These data supported the functional 
changes in glycolysis previously observed; that decreased 
ROS levels correlated with decreased levels of glycolytic 
metabolites. Further support for this data was provided 
by an equivalent experiment using AML patient blast 
samples, which had been categorised into ROSHigh and 
ROSLow producing blasts. Analysis of this data showed 
ROSHigh blasts had higher intracellular glucose levels 
than ROSLow blasts and additionally AML blasts had 
higher levels of intracellular glucose and lactate than 
normal hematopoietic (control) cells [7]. Metabolomic 
data generated as part of our studies [7, 13] also indicated 
increased levels of ROS correlated with alterations in 
metabolites linked to FAO and complex lipid homeostasis. 
NADPH is a crucial electron source for several reductive 
synthesis reactions, including fatty acids, and nucleotides 
which may contribute to sustaining tumor cell growth 
[14]. The generation of NADPH also serves several 
purposes including managing increased oxidative stress 
as NADPH is used as a cofactor by glutathione reductase 
to reduce oxidized glutathione, and by thioredoxin 
reductase to reduce oxidized thioredoxin. In support 
of this, upregulation of the transcription factor Nrf2, 
which regulates gene expression of the peroxiredoxin 
and glutathione systems, as well as pentose phosphate 
pathway (PPP) enzymes such as G-6-PD (reviewed in 
[15]), has been reported in primary cells collected from 
AML patients [16].
ROS has previously been linked to metabolism, 
having been shown in endothelial cells to increase HIF-1α 
expression which in turn upregulates numerous glycolytic 
enzymes [17]. To try to mechanistically understand how 
exposure to ROS leads to changes in PFKFB3 expression, 
our study analysed microarray data for HIF-1α expression 
[7]. The data showed increased expression of HIF-1α 
mRNA correlated with increased ROS levels and given 
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that PFKFB3 is known to be a target of HIF-1α it was 
reasoned that changes in expression may be driving 
PFKFB3 expression. However, HIF-1α is mainly post-
translationally regulated and immunoblotting showed 
that HIF-1α was not expressed at detectable levels and 
furthermore, knock-down of the mRNA for this protein did 
not result in any changes in glucose uptake or proliferation. 
We also investigated the potential role of the stress 
response kinase p38, which is known to be activated in 
response to ROS [18]. Further, the promoter region of the 
PFKFB3 gene contains a serum response element which 
has been shown to be activated by the p38MAPK pathway 
[19]. Whilst activation of p38MAPK by ROS has been shown 
to occur in our studies (unpublished data), inhibition of 
p38MAPK did not lead to changes in PFKFB3 expression. 
ROS is also known to activate both AKT and 
AMPK. We showed that inhibition of mitochondrial 
proteins (UCP2) led to decreased p-AMPK and PFKFB3 
levels [7]. AMPK is a master regulator of cellular energy 
homeostasis, upregulating catabolic metabolic processes 
including increased glycolytic flux and protects against 
ROS accumulation by increasing NADPH production. 
Interestingly, increases in expression of UCP2 has been 
linked with 2–3 fold elevation of plasma fatty acids 
reviewed in [20]. Activation of fatty acid metabolism 
by AMPK (reviewed in [21]) is interesting given that 
ROS activation of AMPK has also been shown to 
potentially maintain HSC [22]. Conversely, inhibition of 
mitochondrial fatty acid oxidation induces loss of HSC 
maintenance [23].
Whilst our studies clearly established a link between 
ROS, PFKFB3 expression, cellular glucose uptake and 
proliferation, several areas warrant further investigation. 
It is often stated as a key tenet of the Warburg effect, that 
transformed cells show an increase in aerobic glycolysis, 
accompanied by increased cellular glucose uptake and 
lactate secretion. Whilst increases in ROS were shown to 
increase cellular glucose uptake, corresponding changes 
in lactate levels were not observed when stratified 
according to ROS level and the reasons for this have not 
been delineated. One plausible explanation is that ROS 
effects changes in monocarboxylate transporter (MCT) or 
LDH expression, resulting in decreased lactate excretion, 
or increased lactate uptake and increased conversion of 
lactate into pyruvate. Given the hydrophilic nature of lactic 
acid, transport across membranes necessitates transporters 
that belong to the MCT family encoded by the solute 
carrier 16 (SCL16) family of genes. The main transporter 
of lactate out of the cell is MCT4 (SLC16A3). While 
MCT4 showed no ROS dependent changes in expression, 
expression of MCT1 (SLC16A1) the main transporter of 
lactate into the cell was not examined (data not shown). 
Overexpression of MCT1 has been observed in several 
cancers and imported lactate can be used for both energy 
production and biosynthesis [24, 25]. In support of this, 
a recent study showed that both HeLa cells and the lung 
cancer cell line H460 use lactate to synthesise lipids 
during proliferation and as an alternative to pyruvate as 
a point of entry into the mitochondria and the generation 
of energy through the citric acid cycle [26]. Furthermore, 
the process of converting pyruvate into lactate additionally 
generates NAD+, which can then be used to support an 
increased glycolytic rate. 
Lactate may also be retained in the cell to promote 
the antioxidant response as lactate is known to inhibit 
PFK activity [27] and thus glycolytic flux. Inhibition of 
glycolytic flux may result in the diversion of glycolytic 
metabolites into the PPP, which is a major metabolic 
pathway in the production of NADPH. Recently it was 
reported that PPP genes were upregulated in > 60% of 
AML patients, whilst inhibition of G-6-PD using the 
inhibitor, 6-aminonictoinamide, inhibited growth and 
migration of AML in vitro [28]. Analysis of metabolomic 
data presented in the study by Robinson et al., is consistent 
with the hypothesis that elevated ROS results in increased 
flux through the PPP.
Current treatments in AML appear to have reached 
their therapeutic limit and the need for either novel stand-
alone therapies or adjuncts to traditional chemotherapeutic 
treatments is clear. There is a growing body of evidence 
implicating aberrant ROS production and redox signalling 
in the modification of cellular metabolic pathways, 
whilst PFKFB3 is known to be dysregulated in numerous 
cancers. Work by our group has established a causal 
link between increased ROS production and changes in 
PFKFB3 expression levels in AML models. However, 
further work is urgently needed to delineate the full impact 
of dysregulated ROS production on cellular metabolic 
function in AML. 
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